An experimental CAR-T therapy, designed to reset the immune system, is demonstrating significant early success in clinical trials for autoimmune diseases. Kathy, diagnosed with lupus shortly after childbirth, became the first patient in the United Kingdom to receive this CAR-T therapy as part of a clinical trial in 2024. Early indicators suggest the treatment is yielding transformative results.
Professor Ben Parker, a rheumatologist who led the trial Kathy participated in, explained the mechanism of the therapy. While specific details on the long-lasting effects on the immune system are still under investigation, the initial outcomes observed in patients like Kathy have been described as astonishing. This therapy, which has been available for over a year, involves modifying a patient's T-cells to target and eliminate the cells responsible for attacking the body's own tissues in autoimmune conditions.
Beyond the CAR-T therapy trials, the program also explored other health-related topics. Medical entomologist Dr. Mojca Kristan and virologist Professor Roger Hewson discussed the increasing presence of mosquitoes, including lab-grown specimens, and the potential threat of diseases they may carry throughout longer periods of the year. Additionally, urologist Professor Vaibhav Modgil addressed the online trend of "spermmaxxing," examining men's practices aimed at optimizing sperm count and quality, such as using iced water on testicles and abstaining from pornography, and assessing the scientific evidence behind these methods.